May 12, 2017 10:24 AM EDT

Capricor shares blasted as PhII heart study fails; Sanofi to destroy unused facility in France

Shehla Shakoor

Managing Director

→ After looking over disappointing interim results from its Phase II study of CAP-1002 for improving outcomes for heart attack patients, Capricor $CAPR is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Capricor shares blasted as PhII heart study fails; Sanofi to destroy unused facility in France

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Capri­cor shares blast­ed as PhII heart study fails; Sanofi to de­stroy un­used fa­cil­i­ty in France

Managing Director

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Capricor shares blasted as PhII heart study fails; Sanofi to destroy unused facility in France